The Alzheimer’s Association celebrates today’s FDA approval of Kisunla™ (donanemab) for the treatment of people living with early symptomatic Alzheimer’s.| Alzheimer's Disease and Dementia
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Leading many to question the state of Alzheimer's research as a whole.| moderndiscontent.substack.com